Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other ... Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Mehr anzeigen
LOS ALTOS, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease...
LOS ALTOS, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease...
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease...
LOS ALTOS, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease...
– On Track to Submit OLC New Drug Application (NDA) by End of August 2024 – LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0133 | -3.31670822943 | 0.401 | 0.4176 | 0.359 | 746414 | 0.38382062 | CS |
| 4 | -0.0063 | -1.59898477157 | 0.394 | 0.43 | 0.2833 | 1597049 | 0.36091523 | CS |
| 12 | -0.1052 | -21.343071617 | 0.4929 | 0.567 | 0.202 | 2444616 | 0.36799325 | CS |
| 26 | -1.0823 | -73.6258503401 | 1.47 | 1.6 | 0.202 | 1392196 | 0.47686824 | CS |
| 52 | -0.2823 | -42.1343283582 | 0.67 | 1.818 | 0.202 | 805850 | 0.55794047 | CS |
| 156 | -2.3523 | -85.8503649635 | 2.74 | 3.13 | 0.202 | 827246 | 1.33854089 | CS |
| 260 | -8.1623 | -95.465497076 | 8.55 | 8.73 | 0.202 | 854808 | 1.58374684 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
